Standard

Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset. / Leonov, Dmitrii A.; Mednova, Irina A.; Chernonosov, Alexander A.

в: Biomedicines, Том 14, № 4, 10.04.2026.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

APA

Vancouver

Leonov DA, Mednova IA, Chernonosov AA. Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset. Biomedicines. 2026 апр. 10;14(4). doi: 10.3390/biomedicines14040872

Author

BibTeX

@article{be9c18c3b46e4f0ebbae7d00b1c046b6,
title = "Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset",
abstract = "Background: Untargeted metabolomics enables comprehensive profiling of biological systems, but accurate metabolite annotation remains a critical bottleneck due to incomplete spectral libraries and structural isomerism. The use of in silico annotation tools can increase the coverage of annotated compounds, but it remains unclear whether these tools, in the absence of reference standards, can reliably annotate real-world experimental LC-HRMS data and whether they are sufficient for this task. Methods: This study assesses the performance and limitations of four widely used in silico structure prediction tools (MassFrontier, MetFrag, MS-FINDER, and SIRIUS/CSI:FingerID) when applied to an experimentally acquired feature set previously used to differentiate patients with depressive disorders from healthy controls. To ensure uniform evaluation across tools under realistic but optimized conditions, the quality of MS/MS data was improved using a parallel reaction monitoring method, allowing acquisition of interpretable fragmentation spectra for 26 of the 28 detected features. Results: For most features, all tools were able to suggest structure candidates. However, none of the tools proved sufficient as a standalone solution for reliable metabolite annotation. Due to their different algorithms, each tool had strengths and weaknesses in fragmentation interpretation, candidate generation, and ranking, resulting in incomplete or inconsistent annotations. While the combined application of all four tools provided a substantial improvement in putative annotation over conventional spectral library matching, the in silico structure prediction tools often prioritized chemically implausible, biologically irrelevant, or artifactual candidates. Consequently, manual expert evaluation was required to assess the chemical plausibility and biological relevance of the proposed structures. This ultimately reduced the number of biologically plausible metabolites putatively associated with disease to ten. Conclusions: Overall, these results demonstrate that existing in silico annotation tools can substantially support the annotation of experimental metabolomics data, but are insufficient on their own. Reliable identification of metabolites in complex biological matrices still depends on high-quality MS/MS data acquisition, the combined use of complementary tools, and mandatory post-annotation expert curation.",
keywords = "MS-FINDER, MassFrontier, MetFrag, PRM, SIRIUS, biomarker discovery, in silico annotation, mass spectrometry, untargeted metabolomics, нецелевая метаболомика, масс-спектрометрия, in silico аннотирование, поиск биомаркеров, PRM, SIRIUS, MetFrag, MS-FINDER, MassFrontier",
author = "Leonov, {Dmitrii A.} and Mednova, {Irina A.} and Chernonosov, {Alexander A.}",
note = "Leonov, D. A. Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset / D. A. Leonov, I. A. Mednova, A. A. Chernonosov // Biomedicines. – 2026. – Vol. 14, No. 4. – P. 872. – DOI 10.3390/biomedicines14040872. – EDN RDJSDO. This research was supported by the joint grant from the Russian Science Foundation No. 25-14-20051 and the Government of the Novosibirsk Region (No. 30-2025-000938). ",
year = "2026",
month = apr,
day = "10",
doi = "10.3390/biomedicines14040872",
language = "English",
volume = "14",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

RIS

TY - JOUR

T1 - Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset

AU - Leonov, Dmitrii A.

AU - Mednova, Irina A.

AU - Chernonosov, Alexander A.

N1 - Leonov, D. A. Evaluation of MassFrontier, MetFrag, MS-FINDER, and SIRIUS for Metabolite Annotation Using an Experimental LC–HRMS Dataset / D. A. Leonov, I. A. Mednova, A. A. Chernonosov // Biomedicines. – 2026. – Vol. 14, No. 4. – P. 872. – DOI 10.3390/biomedicines14040872. – EDN RDJSDO. This research was supported by the joint grant from the Russian Science Foundation No. 25-14-20051 and the Government of the Novosibirsk Region (No. 30-2025-000938).

PY - 2026/4/10

Y1 - 2026/4/10

N2 - Background: Untargeted metabolomics enables comprehensive profiling of biological systems, but accurate metabolite annotation remains a critical bottleneck due to incomplete spectral libraries and structural isomerism. The use of in silico annotation tools can increase the coverage of annotated compounds, but it remains unclear whether these tools, in the absence of reference standards, can reliably annotate real-world experimental LC-HRMS data and whether they are sufficient for this task. Methods: This study assesses the performance and limitations of four widely used in silico structure prediction tools (MassFrontier, MetFrag, MS-FINDER, and SIRIUS/CSI:FingerID) when applied to an experimentally acquired feature set previously used to differentiate patients with depressive disorders from healthy controls. To ensure uniform evaluation across tools under realistic but optimized conditions, the quality of MS/MS data was improved using a parallel reaction monitoring method, allowing acquisition of interpretable fragmentation spectra for 26 of the 28 detected features. Results: For most features, all tools were able to suggest structure candidates. However, none of the tools proved sufficient as a standalone solution for reliable metabolite annotation. Due to their different algorithms, each tool had strengths and weaknesses in fragmentation interpretation, candidate generation, and ranking, resulting in incomplete or inconsistent annotations. While the combined application of all four tools provided a substantial improvement in putative annotation over conventional spectral library matching, the in silico structure prediction tools often prioritized chemically implausible, biologically irrelevant, or artifactual candidates. Consequently, manual expert evaluation was required to assess the chemical plausibility and biological relevance of the proposed structures. This ultimately reduced the number of biologically plausible metabolites putatively associated with disease to ten. Conclusions: Overall, these results demonstrate that existing in silico annotation tools can substantially support the annotation of experimental metabolomics data, but are insufficient on their own. Reliable identification of metabolites in complex biological matrices still depends on high-quality MS/MS data acquisition, the combined use of complementary tools, and mandatory post-annotation expert curation.

AB - Background: Untargeted metabolomics enables comprehensive profiling of biological systems, but accurate metabolite annotation remains a critical bottleneck due to incomplete spectral libraries and structural isomerism. The use of in silico annotation tools can increase the coverage of annotated compounds, but it remains unclear whether these tools, in the absence of reference standards, can reliably annotate real-world experimental LC-HRMS data and whether they are sufficient for this task. Methods: This study assesses the performance and limitations of four widely used in silico structure prediction tools (MassFrontier, MetFrag, MS-FINDER, and SIRIUS/CSI:FingerID) when applied to an experimentally acquired feature set previously used to differentiate patients with depressive disorders from healthy controls. To ensure uniform evaluation across tools under realistic but optimized conditions, the quality of MS/MS data was improved using a parallel reaction monitoring method, allowing acquisition of interpretable fragmentation spectra for 26 of the 28 detected features. Results: For most features, all tools were able to suggest structure candidates. However, none of the tools proved sufficient as a standalone solution for reliable metabolite annotation. Due to their different algorithms, each tool had strengths and weaknesses in fragmentation interpretation, candidate generation, and ranking, resulting in incomplete or inconsistent annotations. While the combined application of all four tools provided a substantial improvement in putative annotation over conventional spectral library matching, the in silico structure prediction tools often prioritized chemically implausible, biologically irrelevant, or artifactual candidates. Consequently, manual expert evaluation was required to assess the chemical plausibility and biological relevance of the proposed structures. This ultimately reduced the number of biologically plausible metabolites putatively associated with disease to ten. Conclusions: Overall, these results demonstrate that existing in silico annotation tools can substantially support the annotation of experimental metabolomics data, but are insufficient on their own. Reliable identification of metabolites in complex biological matrices still depends on high-quality MS/MS data acquisition, the combined use of complementary tools, and mandatory post-annotation expert curation.

KW - MS-FINDER

KW - MassFrontier

KW - MetFrag

KW - PRM

KW - SIRIUS

KW - biomarker discovery

KW - in silico annotation

KW - mass spectrometry

KW - untargeted metabolomics

KW - нецелевая метаболомика

KW - масс-спектрометрия

KW - in silico аннотирование

KW - поиск биомаркеров

KW - PRM

KW - SIRIUS

KW - MetFrag

KW - MS-FINDER

KW - MassFrontier

UR - https://www.mendeley.com/catalogue/ff3670d4-4795-3760-892d-d64f9881d7b0/

UR - https://www.scopus.com/pages/publications/105037214252

UR - https://www.elibrary.ru/item.asp?id=91093238

U2 - 10.3390/biomedicines14040872

DO - 10.3390/biomedicines14040872

M3 - Article

C2 - 42072414

VL - 14

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 4

ER -

ID: 85170565